MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1+ adults immunized with influenza seasonal vaccine.
BACKGROUND
We previously reported that in HIV-1 infected patients circulating Vdelta1 T lymphocytes (Vdelta1) increase and proliferate in vitro in response to Candida albicans (Ca). Herein, we analysed the effects of MF59 adjuvant on the Vdelta1 T cell responses to hemagglutinin (HA) and Ca in HIV-1 seropositive and seronegative adults after influenzal vaccine, to clarify th molecular mechanisms triggered in vivo by an adjuvanted vaccine against influenza virus.


METHODS
58 seropositive (HIV-1+) and 48 seronegative (HIV-1-) subjects received influenzal vaccines containing or not the MF59 adjuvant. The follow-up of in vitro T cell proliferation and cytokine production (IL-17A, IL-22, IL-23, IL-6) to HA and Ca antigens were performed at different time points (at basal time and after 30 and 90 days from vaccination) by cytofluorimetric approaches.


RESULTS
We confirmed that in HIV-1 infected individuals the Vdelta1 T cell subset is expanded in HIV-1 infected individuals and moreover the number of circulating Vdelta1 Tcells significantly enhanced in all HIV-1+ subjects on day 90 after influenza vaccination. Regard the follow-up of proliferative responses, the increments of CD3+ response to HA and Vdelta1 T cells to Ca in HIV-1+ individuals were detectable earlier on day 30 for MF59-vaccinated patients, instead on day 90 post-vaccination in HIV(+)-vaccinated without MF59 adjuvant. Of note, production of lL-17A and IL-22, two cytokines with anti-fungal activity, in response to Ca was enhanced (for IL-17A) or restored (for IL-22) by vaccination in HIV-1+ donors, mainly using the MF59-adjuvanted vaccine. Moreover, after vaccination IL-23 and IL-6 production increased in response to HA in the HIV+ and HIV- groups vaccinated with MF59 adjuvant.


CONCLUSIONS
We suggest that in HIV-1 infected patients the circulating Vdelta1 T lymphocytes reactive to Ca upon challenge with influenza virus vaccine receive an activating/enhancing signal mediated by cytokines triggered by the boost with HA antigen particularly in presence of MF59 adjuvant.
Clinic Immunology Unit, CEBR, University of Genoa, Italy. daniela.fenoglio@unige.it
D
D
Fenoglio
M R
MR
Zocchi
A
A
Parodi
P
P
Durando
G
G
Gabutitp
R
R
Gasparini
A
A
Poggi
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D002176:Candida albicans / Q000276:immunology; D005260:Female; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1; D006388:Hemagglutinins / Q000276:immunology; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology*; D008297:Male; D011136:Polysorbates / Q000008:administration & dosage*; D013185:Squalene / Q000008:administration & dosage*; D016176:T-Lymphocyte Subsets / Q000276:immunology*
D000276:Adjuvants, Immunologic; D006388:Hemagglutinins; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D013185:Squalene